Stock Research for ABIO

ABIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABIO Stock Chart & Research Data

The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABIO Due diligence Resources & Stock Charts

The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABIO Detailed Price Forecast - CNN Money CNN View ABIO Detailed Summary - Google Finance
Yahoo View ABIO Detailed Summary - Yahoo! Finance Zacks View ABIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABIO Trends & Analysis - Trade-Ideas Barrons View ABIO Major Holders - Barrons
NASDAQ View ABIO Call Transcripts - NASDAQ Seeking View ABIO Breaking News & Analysis - Seeking Alpha
Spotlight View ABIO Annual Report - CompanySpotlight.com OTC Report View ABIO OTC Short Report - OTCShortReport.com
TradeKing View ABIO Fundamentals - TradeKing Charts View ABIO SEC Filings - Bar Chart
WSJ View Historical Prices for ABIO - The WSJ Morningstar View Performance/Total Return for ABIO - Morningstar
MarketWatch View the Analyst Estimates for ABIO - MarketWatch CNBC View the Earnings History for ABIO - CNBC
StockMarketWatch View the ABIO Earnings - StockMarketWatch MacroAxis View ABIO Buy or Sell Recommendations - MacroAxis
Bullish View the ABIO Bullish Patterns - American Bulls Short Pains View ABIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABIO Stock Mentions - StockTwits PennyStocks View ABIO Stock Mentions - PennyStockTweets
Twitter View ABIO Stock Mentions - Twitter Invest Hub View ABIO Investment Forum News - Investor Hub
Yahoo View ABIO Stock Mentions - Yahoo! Message Board Seeking Alpha View ABIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABIO - SECform4.com Insider Cow View Insider Transactions for ABIO - Insider Cow
CNBC View ABIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABIO - OTC Markets
Yahoo View Insider Transactions for ABIO - Yahoo! Finance NASDAQ View Institutional Holdings for ABIO - NASDAQ


Stock Charts

FinViz View ABIO Stock Insight & Charts - FinViz.com StockCharts View ABIO Investment Charts - StockCharts.com
BarChart View ABIO Stock Overview & Charts - BarChart Trading View View ABIO User Generated Charts - Trading View




Latest Financial News for ABIO


Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
Posted on Monday March 18, 2019

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Left Ventricles” was recently published in the Journal of the American College of Cardiology (JACC) (http://www.onlinejacc.org/content/73/10/1173). The lead author on the paper is University of Colorado molecular biologist Carmen Sucharov, PhD and the senior author is Michael R. Bristow MD, PhD, ARCA’s Chief Executive Officer, who is also the Director of the University of Colorado Cardiovascular Institute (CU CVI) Section of Pharmacogenomics.


Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
Posted on Wednesday March 06, 2019

WESTMINSTER, Colo., March 06, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.


ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
Posted on Wednesday February 27, 2019

WESTMINSTER, Colo., Feb. 27, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.


ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
Posted on Wednesday February 20, 2019

FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.